CN105943967A - 一种含有蕲蛇的祛湿抗肿瘤中药组合物及其制备方法 - Google Patents
一种含有蕲蛇的祛湿抗肿瘤中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN105943967A CN105943967A CN201610438175.XA CN201610438175A CN105943967A CN 105943967 A CN105943967 A CN 105943967A CN 201610438175 A CN201610438175 A CN 201610438175A CN 105943967 A CN105943967 A CN 105943967A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- agkistrodon
- herba
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 206010028980 Neoplasm Diseases 0.000 title abstract description 23
- 230000000694 effects Effects 0.000 title abstract description 13
- 241000271897 Viperidae Species 0.000 title abstract description 6
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims abstract description 19
- 235000003097 Artemisia absinthium Nutrition 0.000 claims abstract description 19
- 240000001851 Artemisia dracunculus Species 0.000 claims abstract description 19
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims abstract description 19
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims abstract description 19
- 239000001138 artemisia absinthium Substances 0.000 claims abstract description 19
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims abstract description 19
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 18
- 241000756943 Codonopsis Species 0.000 claims abstract description 17
- 241000717739 Boswellia sacra Species 0.000 claims abstract description 16
- 239000004863 Frankincense Substances 0.000 claims abstract description 16
- 241000271039 Agkistrodon Species 0.000 claims description 67
- 239000000843 powder Substances 0.000 claims description 63
- 230000000259 anti-tumor effect Effects 0.000 claims description 28
- 239000000706 filtrate Substances 0.000 claims description 26
- 239000002994 raw material Substances 0.000 claims description 19
- 239000000284 extract Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 241000196324 Embryophyta Species 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 238000001704 evaporation Methods 0.000 claims description 6
- 230000008020 evaporation Effects 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 210000000481 breast Anatomy 0.000 claims description 5
- 239000002304 perfume Substances 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract description 3
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 241000173529 Aconitum napellus Species 0.000 abstract 1
- 241000244987 Daiswa polyphylla Species 0.000 abstract 1
- 235000003805 Musa ABB Group Nutrition 0.000 abstract 1
- 240000008790 Musa x paradisiaca Species 0.000 abstract 1
- 240000001659 Oldenlandia diffusa Species 0.000 abstract 1
- 240000008663 Persicaria orientalis Species 0.000 abstract 1
- 235000015266 Plantago major Nutrition 0.000 abstract 1
- 240000005255 Rubus parvifolius Species 0.000 abstract 1
- 235000018803 Rubus parvifolius Nutrition 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 229940023019 aconite Drugs 0.000 abstract 1
- 230000003750 conditioning effect Effects 0.000 abstract 1
- 238000011127 radiochemotherapy Methods 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 description 20
- 208000026310 Breast neoplasm Diseases 0.000 description 20
- 208000002193 Pain Diseases 0.000 description 14
- 230000036407 pain Effects 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 12
- 201000008275 breast carcinoma Diseases 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 230000035619 diuresis Effects 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000012736 patent blue V Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 208000002881 Colic Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 210000003026 hypopharynx Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000006379 syphilis Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010066968 Corneal leukoma Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 241000825107 Hierochloe Species 0.000 description 1
- 235000015466 Hierochloe odorata Nutrition 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000008763 Mercury poisoning Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 206010062104 Renal mass Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 241001251949 Xanthium sibiricum Species 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 150000001719 carbohydrate derivatives Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000009748 deglutition Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- -1 hydroxy-propyl Chemical group 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000010553 multiple abscesses Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000004084 narcotic analgesic agent Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/583—Snakes; Lizards, e.g. chameleons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种含有蕲蛇的祛湿抗肿瘤中药组合物及其制备方法，包括以下重量份的原料：蕲蛇10～18份、土茯苓25～28份、肉桂20～22份、绵茵陈20～25份、白花蛇舌草18～23份、玄参20～25份、天青地白草20～25份、鲜车前草25～30份、乳香30～40份、白芷20～25份、生草乌30～40份、黄芩18～25份、草河车20～24份、党参20～25份、灸甘草20～28份、水红花子8～12份、茵陈12～18份和白芍15～18份。本发明中药组合物在治疗肿瘤方面成本低、毒副作用小、治疗效果好，对于因长期放化疗而羸弱的身体有极好的调理作用。
Description
技术领域
本发明涉及一种含有蕲蛇的祛湿抗肿瘤中药组合物及其制备方法，属于治疗肿瘤的中药领域。
背景技术
肿瘤(Tumor)是目前危害人类健康的主要疾病之一,是由多种因素引发人体的组织细胞反应性异常增生的一种常见病，目前全球医药市场对安全、有效的抗肿瘤药物存在巨大需求空间。肿瘤最基本的生物学特征是细胞生长失控，寻找对肿瘤细胞生长具有靶向抑制作用的抗肿瘤药是药物研发者的重要课题。当前治疗肿瘤的手段主要包括化疗、放疗和手术治疗。但大量的临床治疗证明，化疗和放疗在杀伤肿瘤细胞的同时对机体正常细胞具有损害作用。
中药抗肿瘤具有作用机制独特、药效持久、多靶点、多途径、抗肿瘤谱广、毒副作用小等优点，对于治疗肿瘤具有巨大的潜力和不可替代的优势，如今在临床上已经逐步占据了主导地位。现已发现的抗肿瘤药物中，源于植物的占32.25％。从天然植物中寻找抗肿瘤活性成分是当前及今后一段时期内抗肿瘤药物研发的热点。
发明内容
本发明所要解决的技术问题是提供一种含有蕲蛇的祛湿抗肿瘤中药组合物及其制备方法，有效利用天然植物原料实现减少化疗、放疗和手术治疗等对人体的二次损害。
本发明解决上述技术问题的技术方案如下：一种含有蕲蛇的祛湿抗肿瘤中药组合物，包括以下重量份的原料：蕲蛇10～18份、土茯苓25～28份、肉桂20～22份、绵茵陈20～25份、白花蛇舌草18～23份、玄参20～25份、天青地白草20～25份、鲜车前草25～30份、乳香30～40份、白芷20～25份、生草乌30～40份、黄芩18～25份、草河车20～24份、党参20～25份、灸甘草20～28份、水红花子8～12份、茵陈12～18份和白芍15～18份。
本发明的有益效果是：在治疗肿瘤方面成本低、毒副作用小、治疗效果好，对于因长期放化疗而羸弱的身体有极好的调理作用。
在上述技术方案的基础上，本发明还可以做如下改进。
本发明如上所述一种含有蕲蛇的祛湿抗肿瘤中药组合物，进一步，包括以下重量份的原料：蕲蛇15份、土茯苓25份、肉桂20份、绵茵陈23份、白花蛇舌草20份、玄参22份、天青地白草23份、鲜车前草26份、乳香35份、白芷24份、生草乌35份、党参22份、灸甘草25份、水红花子10份、茵陈15份和白芍17份。
本发明如上所述一种含有蕲蛇的祛湿抗肿瘤中药组合物，进一步，包括以下重量份的原料：蕲蛇16份、土茯苓27份、肉桂22份、绵茵陈23份、白花蛇舌草22份、玄参24份、天青地白草23份、鲜车前草27份、乳香36份、白芷24份、生草乌34份、党参23份、灸甘草25份、水红花子10份、茵陈17份和白芍16份。
本发明如上所述一种含有蕲蛇的祛湿抗肿瘤中药组合物，进一步，包括以下重量份的原料：蕲蛇13份、土茯苓26份、肉桂20份、绵茵陈24份、白花蛇舌草19份、玄参24份、天青地白草23份、鲜车前草26份、乳香33份、白芷24份、生草乌38份、党参25份、灸甘草22份、水红花子11份、茵陈15份和白芍16份。
本发明如上所述一种含有蕲蛇的祛湿抗肿瘤中药组合物，进一步，还包括萆薢18～20份。
本发明采用进一步的有益效果是：增加萆薢蕲蛇可以助主药蕲蛇、土茯苓、绵茵陈、肉桂、绵茵陈、白花蛇舌草、玄参、天青地白草、鲜车前草、乳香、白芷、生草乌、党参、灸甘草、水红花子、茵陈和白芍祛湿健脾。
本发明如上所述一种含有蕲蛇的祛湿抗肿瘤中药组合物，进一步，还包括萆薢19份。
上述植物原料通过加6～10倍量水浸泡1～2小时，水煎提取0.5～3小时，过滤，收集滤液；滤渣加5～8倍量水，水煎提取0.5～2小时，过滤，收集滤液；合并滤液；取蕲蛇砍去头尾，用黄酒浸润后，置蒸笼内蒸透，除去皮骨，晒干，研磨成蕲蛇粉，滤液和蕲蛇粉混合均匀。上述滤液蒸发挥去液体制备成浸膏，浸膏和蕲蛇粉混合均匀。所述浸膏于烘箱中80℃烘烤至完全干燥后粉碎成植物细粉，植物细粉和蕲蛇粉混合均匀成细粉。上述植物原料也可以混合通过乙醇萃取获得萃取液，萃取液浓缩制备成浸膏。
上述细粉也可以通过加入制备不同剂型时需要的各种常规辅料，按常规的中药制剂方法制备成常见中药制剂剂型。
本发明中，所用的药用辅料，可以选自于粘合剂(可以是聚维酮、淀粉浆、纤维素等)、崩解剂(可以是干燥淀粉、羧甲基纤维素钠、低取代羟丙基纤维素、聚乙烯比咯烷酮等)、润滑剂(可以是滑石粉、硬脂酸、硬脂酸钙镁、硬脂酸钙等)、矫味剂(可以是蔗糖、阿司巴甜、甜菊素、果糖等)、稳定剂(可以是对羟基苯甲酸甲酯、对羟基苯甲酸丙酯等)、稀释剂(可以是淀粉、糊精、糖粉、乳糖等)、润湿剂(可以是水或乙醇)、助流剂(可以是微粉硅胶)、赋形剂(可以是糖类衍生物如乳糖、蔗糖、葡萄糖、甘露醇、山梨醇；淀粉类衍生物如玉米淀粉、土豆淀粉、糊精或羧甲基淀粉；纤维素衍生物如结晶纤维、羟丙基纤维、羧甲基纤维。
所述的一种治疗乳腺癌及乳腺增生的中药组合物在制备抗种治疗乳腺癌及乳腺增生药物中的应用。
所述的抗肿瘤中药是促肿瘤细胞凋亡的药物。
本发明以上原料具体的功能效果如下：
蕲蛇：别名为棋盘蛇、五步蛇、百步蛇。性味归经为甘、咸，温，有毒。归肝经。有祛风，活络，定经的功效。
土茯苓：性味：甘淡，平。归经：肝经；胃经；脾经。解毒，除湿，利关节。主治：治梅毒，淋浊，筋骨挛痛，脚气，疗疔疮，痈肿，瘰疬，梅毒及汞中毒所致的肢体拘挛，筋骨疼痛。
肉桂：性大热，味辛、甘。治命门火衰，肢冷脉微，亡阳虚脱，腹痛泄泻，寒疝奔豚，腰膝冷痛，经闭症瘕，阴疽，流注，及虚阳浮越，上热下寒。
绵茵陈：气味苦，平、微寒，无毒。
白花蛇舌草：其成药味苦、淡，性寒。主要功效是清热解毒、消痛散结、利尿除湿。
玄参：温热病热和营血、身热、烦渴、舌绛、发斑、骨蒸劳嗽、虚烦不寤、津伤便秘、目涩昏花、咽喉喉肿痛、瘰疬痰核、痈疽疮毒。
天青地白草：清热利湿，解毒消肿。主治结膜炎，角膜白斑，感冒，咳嗽，咽喉肿痛，尿道炎；外用治乳腺炎，痈疖肿毒，毒蛇咬伤。
鲜车前草：性甘；淡；性微寒；归肺经；肝经；肾经；膀胱经，具有清热利尿；渗湿止泻；明目；祛痰功效。
乳香：入心、肝、脾经，调气活血，定痛，追毒。治气血凝滞、心腹疼痛，痈疮肿毒，跌打损伤，痛经，产后瘀血刺痛。
白芷：性温，味辛，气芳香，微苦，祛风湿，活血排脓，生肌止痛。用于头痛、牙痛、鼻渊、肠风痔漏、赤白带下、痈疽疮疡、皮肤瘙痒。
生草乌：辛、苦，热；有大毒。归心、肝、肾、脾经。祛风除湿，温经止痛。用于风寒湿痹，关节疼痛，心腹冷痛，寒疝作痛，麻醉止痛。
党参：性平，味甘、微酸。归脾、肺经，补中益气，健脾益肺。用于脾肺虚弱，气短心悸，食少便溏，虚喘咳嗽，内热消渴。
灸甘草：甘，平。归心、脾、肺、胃经。补脾和胃，益气复脉。脾胃虚弱，倦怠乏力，心动悸，脉结代。
水红花子：有散血消症，消积止痛，利水消肿功能。用于痞块腹胀，肝脾肿大，颈淋巴结核，消渴，胃痛。
茵陈：清热利湿；退黄，有利胆促进胆汁分泌，增加胆汁中胆酸和胆红素排出的作用.能增加心脏冠脉血流量,改善微循环，并有降血压,降血脂，抗凝血,利尿解热平喘。
白芍：白芍性凉，味苦酸，微寒，具有补血柔肝、平肝止痛，芍药甙有抗菌、解热、抗炎、增加冠状动脉流量、改善心肌营养血流、扩张血管、对抗急性心肌缺血、抑制血小板聚集、镇静、镇痛、解痉、抗溃疡、调节血糖的作用。
具体实施方式
结合以下实施例对本发明的原理和特征进行描述，所举实例只用于解释本发明，并非用于限定本发明的范围。
实施例1
一种含有蕲蛇的祛湿抗肿瘤中药组合物，包括以下的原料：蕲蛇15g、土茯苓25g、肉桂20g、绵茵陈23g、白花蛇舌草20g、玄参22g、天青地白草23g、鲜车前草26g、乳香35g、白芷24g、生草乌35g、党参22g、灸甘草25g、水红花子10g、茵陈15g和白芍17g。
上述植物原料通过加6倍量水浸泡2小时，水煎提取3小时，过滤，收集滤液；滤渣加8倍量水，水煎提取2小时，过滤，收集滤液；合并滤液，取蕲蛇砍去头尾，用黄酒浸润后，置蒸笼内蒸透，除去皮骨，晒干，研磨成蕲蛇粉。上述滤液蒸发挥去液体制备成浸膏。该浸膏也可以于烘箱中80℃烘烤至完全干燥后，浸膏干燥粉碎后与蕲蛇粉混合均匀成细粉；该细粉活性成分可以制成胶囊制剂，该浸膏可以烘干制成粉剂。
实施例2
本发明如上所述一种含有蕲蛇的祛湿抗肿瘤中药组合物，包括以下的原料：蕲蛇16g、土茯苓27g、肉桂22g、绵茵陈23g、白花蛇舌草22g、玄参24g、天青地白草23g、鲜车前草27g、乳香36g、白芷24g、生草乌34g、党参23g、灸甘草25g、水红花子10g、茵陈17g和白芍16g。上植物述原料混合通过乙醇萃取获得萃取液，浓缩制成活性物浸膏，该浸膏可以烘干后与蕲蛇粉混合均匀成细粉。
实施例3
本发明如上所述一种含有蕲蛇的祛湿抗肿瘤中药组合物，包括以下的原料：蕲蛇13g、土茯苓26g、肉桂20g、绵茵陈24g、白花蛇舌草19g、玄参24g、天青地白草23g、鲜车前草26g、乳香33g、白芷24g、生草乌38g、党参25g、灸甘草22g、水红花子11g、茵陈15g和白芍16g。上述植物原料混合通过乙醇萃取获得萃取液，浓缩制成活性物浸膏；取蕲蛇砍去头尾，用黄酒浸润后，置蒸笼内蒸透，除去皮骨，晒干，研磨成蕲蛇粉，该浸膏可以烘干后与蕲蛇粉混合均匀成细粉。
实施例4
本发明如上所述一种含有蕲蛇的祛湿抗肿瘤中药组合物，包括以下的原料：蕲蛇13g、土茯苓26g、肉桂20g、绵茵陈24g、白花蛇舌草19g、玄参24g、天青地白草23g、鲜车前草26g、乳香33g、白芷24g、生草乌38g、党参25g、灸甘草22g、水红花子11g、茵陈15g、白芍16g和萆薢19g。
上述植物原料通过加6倍量水浸泡1小时，水煎提取0.5小时，过滤，收集滤液；滤渣加5倍量水，水煎提取0.5小时，过滤，收集滤液，取蕲蛇砍去头尾，用黄酒浸润后，置蒸笼内蒸透，除去皮骨，晒干，研磨成蕲蛇粉；合并滤液。上述滤液蒸发挥去液体制备成浸膏，该浸膏可以烘干后与蕲蛇粉混合均匀成细粉。
实施例5
本发明一种含有蕲蛇的祛湿抗肿瘤中药组合物，包括以下的原料：蕲蛇10g、土茯苓25g、肉桂20g、绵茵陈20g、白花蛇舌草18g、玄参20g、天青地白草20g、鲜车前草25g、乳香30g、白芷20g、生草乌30g、黄芩18g、草河车20g、党参20g、灸甘草20g、水红花子8g、茵陈12g和白芍15g。
上述植物原料通过加6倍量水浸泡1小时，水煎提取0.5小时，过滤，收集滤液；滤渣加8倍量水，水煎提取0.5小时，过滤，收集滤液；合并滤液；取蕲蛇砍去头尾，用黄酒浸润后，置蒸笼内蒸透，除去皮骨，晒干，研磨成蕲蛇粉。上述滤液蒸发挥去液体制备成浸膏。该浸膏可以烘干后与蕲蛇粉混合均匀成细粉。
实施例6
本发明一种含有蕲蛇的祛湿抗肿瘤中药组合物，包括以下的原料：蕲蛇18g、土茯苓28g、肉桂22g、绵茵陈25g、白花蛇舌草23g、玄参25g、天青地白草25g、鲜车前草30g、乳香40g、白芷25g、生草乌40g、黄芩25g、草河车24g、党参25g、灸甘草28g、水红花子12g、茵陈18g和白芍18g。
上述原料通过加6倍量水浸泡1小时，水煎提取2小时，过滤，收集滤液；滤渣加6倍量水，水煎提取2小时，过滤，收集滤液；合并滤液，取蕲蛇砍去头尾，用黄酒浸润后，置蒸笼内蒸透，除去皮骨，晒干，研磨成蕲蛇粉。上述滤液蒸发挥去液体制备成浸膏，该浸膏可以烘干后与蕲蛇粉混合均匀成细粉。
上述浸膏也可以直接涂覆在肿块外的皮肤表面。
急性毒理试验
试验动物：ICR小鼠60只，体重17～22g，雌雄各半。来自天津大学医学院实验室；
动物分组：采用雌雄分别随机均衡分组法，共分为6组，每组10只，其中一组为空白对照组。
剂量确定：计量设计为：实施例1的粉剂10g/kg，粉剂20g/kg(临床设计给药剂量)，粉剂30g/kg，粉剂40g/kg、粉剂50g/kg。
给药：一次性灌胃给药：给药前禁食3～5小时，给药后禁食1～2小时，禁食不禁水。采用分批给药，阴性对照组，粉剂10g/kg，相当原药15g/kg的第一批给药，给药后确定所设剂量合适，再给予粉剂20g/kg、粉剂30g/kg、粉剂40g/kg、粉剂50g/kg。给药后连续观察7天以上，随后每天上、下午各观察一次，连续观察14天。详细记录各项观察指标表1。
表1.急性毒理试验结果
| 组别 | 粉剂/kg | 数量 | 存活率％ |
| 1 | 10 | 100 | |
| 2 | 10 | 10 | 100 |
| 3 | 20 | 10 | 100 |
| 4 | 30 | 10 | 100 |
| 5 | 40 | 10 | 100 |
| 6 | 50 | 10 | 100 |
结论：受试物在本试验中灌胃给药剂量达到粉剂50g/kg时，未出现死亡。按照急性毒性分级标准判定，本受试药物可视为低毒。
长期毒性试验
大鼠一般6～9周龄。试验开始时体重差异不应超过或者低于该次试验动物平均体重的20％；
试验分组：一般设5个剂量组和一个对照组。
剂量确定：计量设计为：实施例1的粉剂10g/kg，粉剂20g/kg(临床设计给药剂量)，粉剂30g/kg，粉剂40g/kg、粉剂50g/kg。
反复给药：一次性灌胃给药：给药前禁食3～5小时，给药后禁食1～2小时，禁食不禁水。采用分批给药，阴性对照组，粉剂10g/kg，粉剂15g/kg的第一批给药，给药后确定所设剂量合适，再给予粉剂20g/kg、粉剂30g/kg、粉剂40g/kg、粉剂50g/kg。连续给药6个月后停止用药，连续观察1个月天以上。详细记录各项观察指标表2。
表2.长期毒理试验结果
| 组别 | 粉剂/kg | 数量 | 存活率％ |
| 1 | 10 | 100 | |
| 2 | 10 | 10 | 100 |
| 3 | 20 | 10 | 100 |
| 4 | 30 | 10 | 100 |
| 5 | 40 | 10 | 99 |
| 6 | 50 | 10 | 98 |
结论：受试物在本试验中灌胃给药剂量达到粉剂50g/kg时，有个别死亡。按照长期毒性分级标准判定，本受试药物可视为低毒或无毒。
实施例1至实施例6，对于乳腺癌，上述浸膏涂可以直接采用抹于乳房上，每天3次，每次2g，可以用保鲜膜等包覆10～30分钟。
上述实施例1至实施例6细粉可加入制备不同剂型的各种常规辅料，按常规的中药制剂方法制备成常见中药制剂剂型，如片剂、胶囊剂、口服液、冲剂等。
本发明实验例1中药组合物对小鼠乳腺癌肿瘤转移的影响
小鼠乳腺癌模型建立：取生长良好的4T1乳腺癌传代实体瘤，用生理盐水制备瘤细胞悬液，调细胞数5×106个细胞/ml，按0.1ml/只接种于40只BALB/c小鼠乳房脂肪垫下，将小鼠随机分成4组，每组10只，按以下方法治疗。
本发明中药组合物剂量组包括高剂量组(20g/kg)，中剂量组(10g/kg)，低剂量组(5g/kg)；每日灌胃给药一次，连续14日；对照组给予等量生理盐水，于停药次日处死小鼠，称体重，剥离肺脏及转移结节，计算乳腺癌肺转移抑制率，结果见下表3。
表3.中药组合物对小鼠乳腺癌肿瘤转移转移抑制率
实施例5本发明中药组合物对小鼠乳腺癌肿瘤转移的影响
小鼠乳腺癌模型建立：取生长良好的4T1乳腺癌传代实体瘤，用生理盐水制备瘤细胞悬液，调细胞数5×106个细胞/ml，按0.1ml/只接种于40只BALB/c小鼠乳房脂肪垫下，将小鼠随机分成4组，每组10只，按以下方法治疗。
本发明中药组合物剂量组包括高剂量组(20g/kg)，中剂量组(10g/kg)，低剂量组(5g/kg)；每日灌胃给药一次，连续14日；对照组给予等量生理盐水，于停药次日处死小鼠，称体重，剥离肺脏及转移结节，计算乳腺癌肺转移抑制率，结果见下表4。
表4.中药组合物对小鼠乳腺癌肿瘤转移转移抑制率
本发明实验例4中药组合物对小鼠乳腺癌肿瘤转移的影响
小鼠乳腺癌模型建立：取生长良好的4T1乳腺癌传代实体瘤，用生理盐水制备瘤细胞悬液，调细胞数5×106个细胞/ml，按0.1ml/只接种于40只BALB/c小鼠乳房脂肪垫下，将小鼠随机分成4组，每组10只，按以下方法治疗。
本发明中药组合物剂量组包括高剂量组(20g/kg)，中剂量组(10g/kg)，低剂量组(5g/kg)；每日灌胃给药一次，连续14日；对照组给予等量生理盐水，于停药次日处死小鼠，称体重，剥离肺脏及转移结节，计算乳腺癌肺转移抑制率，结果见下表5。
表5.中药组合物对小鼠乳腺癌肿瘤转移转移抑制率
以上实验可以看出，增加了特定比例萆薢，可以有效提高肿瘤抑制率。
典型病例
秦某，女，山西人，45岁，在市级医院确诊右乳腺癌，转至省肿瘤医院进行右乳全切术，化疗两个疗程之后出现昏迷低烧细菌感染，抢救治疗后仍出现反复发烧，再次转院到省人民医院治疗仍出现在反复发烧行走不便，需要别人搀扶，服用本发明实施例1中药治疗，粉剂计量按照每天50g的量进行服用，患者病情很快得到有效控制，时隔三个月，患者复诊时，症状全消，各项指标，与常人无异，发现该中药是患者的福音。
王某，44岁，在省医院确诊为右乳腺癌，随后在卫生院做切除手术，术后进行了4个疗程的化疗。因发现右颈和右胸部有部肿块，在医院复查，病理显示符合淋巴结内癌转移，并随即进行了15次放疗，消瘦，面黄，乏力，右颈部因放疗皮肤焦黑，右颈部隐痛、手触有明显肿块，左胸偶尔有痛感。随后服用本发明实施例2中药治疗，用药后即见效果，右颈部、左胸痛感缓解，食欲大增，行动有力，经过两个疗程的持续用药，体重增加3斤，面色红润，浑身有力，右颈部焦黑皮肤颜色变浅，右颈部、左胸均无痛感右颈部肿块明显缩小。
常某，男，48岁，重庆人，症状：吃东西下咽困难，体重下降，间歇性咽部疼痛而且声音嘶哑，伴有严重呕吐，去医院诊断为咽喉癌，病龄：5个月。服用本发明中药粉剂，每日20g剂分2次口服，饭后2小时口服，使用本发明中药组合物治疗8天，呕吐症状减轻，疼痛有很大的缓解；使用本发明中药组合物治疗2个月，吞咽功能完全恢复，经医院检查肿瘤明显变小。使用本发明中药组合物治疗12个月，肿瘤消失，至今无复发。
本发明可以用于各种肿瘤的治疗，且疗效显著。
以上所述仅为本发明的较佳实施例，并不用以限制本发明，凡在本发明的精神和原则之内，所作的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
Claims (9)
1.一种含有蕲蛇的祛湿抗肿瘤中药组合物，其特征在于，包括以下重量份的原料：蕲蛇10～18份、土茯苓25～28份、肉桂20～22份、绵茵陈20～25份、白花蛇舌草18～23份、玄参20～25份、天青地白草20～25份、鲜车前草25～30份、乳香30～40份、白芷20～25份、生草乌30～40份、黄芩18～25份、草河车20～24份、党参20～25份、灸甘草20～28份、水红花子8～12份、茵陈12～18份和白芍15～18份。
2.根据权利要求1所述一种含有蕲蛇的祛湿抗肿瘤中药组合物，其特征在于，包括以下重量份的原料：蕲蛇15份、土茯苓25份、肉桂20份、绵茵陈23份、白花蛇舌草20份、玄参22份、天青地白草23份、鲜车前草26份、乳香35份、白芷24份、生草乌35份、党参22份、灸甘草25份、水红花子10份、茵陈15份和白芍17份。
3.根据权利要求1所述一种含有蕲蛇的祛湿抗肿瘤中药组合物，其特征在于，包括以下重量份的原料：蕲蛇16份、土茯苓27份、肉桂22份、绵茵陈23份、白花蛇舌草22份、玄参24份、天青地白草23份、鲜车前草27份、乳香36份、白芷24份、生草乌34份、党参23份、灸甘草25份、水红花子10份、茵陈17份和白芍16份。
4.根据权利要求1所述一种含有蕲蛇的祛湿抗肿瘤中药组合物，其特征在于，包括以下重量份的原料：蕲蛇13份、土茯苓26份、肉桂20份、绵茵陈24份、白花蛇舌草19份、玄参24份、天青地白草23份、鲜车前草26份、乳香33份、白芷24份、生草乌38份、党参25份、灸甘草22份、水红花子11份、茵陈15份和白芍16份。
5.根据权利要求1至4任一项所述一种含有蕲蛇的祛湿抗肿瘤中药组合物，其特征在于，还包括萆薢18～20份。
6.根据权利要求5所述一种含有蕲蛇的祛湿抗肿瘤中药组合物，其特征在于，还包括萆薢19份。
7.一种含有蕲蛇的祛湿抗肿瘤中药组合物的制备方法，其特征在于，按照权利要求1至6任一项所述重量份称取原料，上述植物原料通过加6～10倍量水浸泡1～2小时，水煎提取0.5～3小时，过滤，收集滤液；滤渣加5～8倍量水，水煎提取0.5～2小时，过滤，收集滤液；合并滤液；取蕲蛇砍去头尾，用黄酒浸润后，置蒸笼内蒸透，除去皮骨，晒干，研磨成蕲蛇粉，滤液和蕲蛇粉混合均匀。
8.根据权利要求7所述一种含有蕲蛇的祛湿抗肿瘤中药组合物的制备方法，其特征在于，所述滤液蒸发挥去液体制备成浸膏，浸膏和蕲蛇粉混合均匀。
9.根据权利要求8所述一种含有蕲蛇的祛湿抗肿瘤中药组合物的制备方法，其特征在于，所述浸膏于烘箱中80℃烘烤至完全干燥后粉碎成植物细粉，植物细粉和蕲蛇粉混合均匀成细粉。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610438175.XA CN105943967A (zh) | 2016-06-20 | 2016-06-20 | 一种含有蕲蛇的祛湿抗肿瘤中药组合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610438175.XA CN105943967A (zh) | 2016-06-20 | 2016-06-20 | 一种含有蕲蛇的祛湿抗肿瘤中药组合物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105943967A true CN105943967A (zh) | 2016-09-21 |
Family
ID=56907166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610438175.XA Withdrawn CN105943967A (zh) | 2016-06-20 | 2016-06-20 | 一种含有蕲蛇的祛湿抗肿瘤中药组合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105943967A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110433260A (zh) * | 2019-08-23 | 2019-11-12 | 北京市中医研究所 | 一种用于治疗银屑病的药物组合物及其制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1562162A (zh) * | 2004-03-23 | 2005-01-12 | 天津市天骄制药有限公司 | 一种克癌中药组合物及其制备方法 |
| CN101053645A (zh) * | 2006-04-10 | 2007-10-17 | 张华锋 | 一种治疗肿瘤黄膏药及制备方法 |
| CN102861312A (zh) * | 2012-10-05 | 2013-01-09 | 董洪海 | 一种用于治疗骨关节炎及肿瘤病的膏药 |
| CN103054981A (zh) * | 2013-01-31 | 2013-04-24 | 邵宏敏 | 一种治疗腹腔恶性肿瘤的外用中药 |
-
2016
- 2016-06-20 CN CN201610438175.XA patent/CN105943967A/zh not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1562162A (zh) * | 2004-03-23 | 2005-01-12 | 天津市天骄制药有限公司 | 一种克癌中药组合物及其制备方法 |
| CN101053645A (zh) * | 2006-04-10 | 2007-10-17 | 张华锋 | 一种治疗肿瘤黄膏药及制备方法 |
| CN102861312A (zh) * | 2012-10-05 | 2013-01-09 | 董洪海 | 一种用于治疗骨关节炎及肿瘤病的膏药 |
| CN103054981A (zh) * | 2013-01-31 | 2013-04-24 | 邵宏敏 | 一种治疗腹腔恶性肿瘤的外用中药 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110433260A (zh) * | 2019-08-23 | 2019-11-12 | 北京市中医研究所 | 一种用于治疗银屑病的药物组合物及其制备方法 |
| CN110433260B (zh) * | 2019-08-23 | 2021-06-25 | 北京市中医研究所 | 一种用于治疗银屑病的药物组合物及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104352991A (zh) | 一种治疗痛风的中药制剂及其制备方法 | |
| CN100375634C (zh) | 一种用于艾灸的药物及其制备方法 | |
| CN102961648B (zh) | 一种治疗晚期大肠癌的中药复方制剂 | |
| CN104225441A (zh) | 一种治疗胃病的中药组合物及其颗粒剂和胶囊剂的制备方法 | |
| CN103520572A (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
| CN104324328A (zh) | 一种用于肠梗阻的中药组合物及其制备方法 | |
| CN104436018A (zh) | 治疗肿瘤的药物及其制备方法 | |
| CN103463297A (zh) | 一种治疗阴囊湿疹的中药组合物及其制备方法和用途 | |
| CN104771578A (zh) | 用于治疗变应性鼻炎的中药 | |
| CN104784549A (zh) | 用于治疗变应性鼻炎的内服中药 | |
| CN105943967A (zh) | 一种含有蕲蛇的祛湿抗肿瘤中药组合物及其制备方法 | |
| CN105106634A (zh) | 一种治疗急性阑尾炎的中药制剂及其应用 | |
| CN104873911A (zh) | 一种辅助治疗脓毒症的内服中药 | |
| CN104998158A (zh) | 一种治疗肝硬化的药物组合物及其应用 | |
| CN104825892B (zh) | 一种治疗排卵期出血的中药制剂及其制备方法 | |
| CN103751650A (zh) | 一种治疗痛风缓解期的中药组合物及其制备方法 | |
| CN103860844B (zh) | 一种治疗慢性结肠炎的中药制剂及其制备方法 | |
| CN104721786A (zh) | 一种治疗妊娠肝内胆汁淤积症的中药制剂及其制备方法 | |
| CN105311564A (zh) | 一种治疗淋巴癌的疏肝解郁制剂及制备方法 | |
| CN105250417A (zh) | 一种治疗腹泻型肠易激综合征的药物组合物及其应用 | |
| CN105381410A (zh) | 一种治疗肝炎的中药制剂 | |
| CN105168774A (zh) | 一种治疗肩周炎的中药制剂及其制备方法 | |
| CN104622983A (zh) | 治疗直肠炎的中药组合物及其制备方法 | |
| CN104758749A (zh) | 一种治疗肝癌的中药组合物 | |
| CN103611098B (zh) | 一种治疗皮肤瘙痒的中药 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160921 |
|
| WW01 | Invention patent application withdrawn after publication |